AlexandraGatelyCornellMDMCR

Pediatric Pulmonology • Boston, MA

Chronic Lung Disease of Prematurity and Infancy, Cystic Fibrosis Pulmonology, Pediatric Asthma Pulmonology

Senior Medical Director, Merck Cardiovascular & Respiratory Clinical Research

Join to view full profile

Dr. Cornell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cornell's full profile

Already have an account?

Office
33 Avenue Louis Pasteur
Boston, MA 02115

Education & Training

OHSUMCR, Clinical Research, 2013 - 2018
NYP Hosp-Columbia Univ Med Ctr2011
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Pediatrics, 2005 - 2008
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalInternship, Pediatrics, 2005 - 2006
University of Vermont College of MedicineClass of 2005

Certifications & Licensure

MA State Medical License 2019 - 2026
OR State Medical License 2013 - 2021
NH State Medical License Active through 2013
NY State Medical License 2008 - 2012
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Pulmonology

Clinical Trials

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Start of enrollment: 2013 Jul 01
Completed
Phase 3
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis Start of enrollment: 2014 Jun 01
Completed
Phase 3
Saline Hypertonic in Preschoolers Start of enrollment: 2015 Mar 01
Completed
Not Applicable
Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor Start of enrollment: 2015 Aug 01
Completed
Phase 3
A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Start of enrollment: 2017 May 12
Completed
Phase 3
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Start of enrollment: 2018 Sep 07
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

78 citations
Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial
Felix Ratjen, Stephanie D. Davis, Sanja Stanojevic, Richard A. Kronmal, Karen Hinckley Stukovsky
The Lancet. Respiratory Medicine. 2019-09-01
210 citations
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled, phase 3...
Felix Ratjen, Christopher Hug, Gautham Marigowda, S. Tian, Xiaohong Huang
The Lancet. Respiratory Medicine. 2017-07-01
23 citations
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, ...
Jordana E. Hoppe, Mark A. Chilvers, Felix Ratjen, John McNamara, Caroline A. Owen
The Lancet. Respiratory Medicine. 2021-05-06

Journal Articles

Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, ope...
Chilvers MA, Davies JC, Milla C, Tian S, Han Z, Cornell AG, Owen CA, Ratjen F, Lancet Respiratory Medicine, 1/28/2021

Professional Memberships

American Academy of Pediatrics - AAP
Fellow
American Thoracic Society - ATS
Member